L S C
Lymphoedema Support Clinic
Donna Bastin
A monitoring programme offers patients peace of mind.
Understand your L‑Dex (lymphoedema index) score with the leading technology for point-of-care lymphoedema assessment.
Clinical Evidence
ImpediMed’s bioimpedance spectroscopy (BIS) devices have been studied
and clinically validated in the areas of lymphoedema
References
-
Shah C, et al. The impact of monitoring techniques on progression to chronic breast cancer‑related lymphedema: a meta‑analysis comparing bioimpedance spectroscopy versus circumferential measurements. Breast Cancer Research and Treatment 2020; https://doi.org/10.1007/s10549-020-05988-6.
-
https://lymphaticnetwork.org/treating-lymphedema. Accessed September 12, 2019.
-
Ridner SH, et al. A Randomized Trial Evaluating Bioimpedance Spectroscopy Versus Tape Measurement for the Prevention of Lymphedema Following Treatment for Breast Cancer: Interim Analysis. Ann Surg Oncol 2019; https://doi.org/10.1245/s10434-019-07344-5.
-
American Cancer Society’s Cancer Facts and Figures, 2019. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf
-
Shaitelman SF, et al. Recent Progress in the Treatment and Prevention of Cancer-Related Lymphedema. CA Cancer J Clin. 2015;00:00–00.
-
Brown JC, et al. The Prevalence of Lymphedema Symptoms among Long-Term Cancer Survivors with or at-risk for Lower Limb Lymphedema. Am J Phys Med Rehabil. 2013 March ; 92(3): 223–231. doi:10.1097/PHM.0b013e31826edd97.
-
Herd-Smith, A., et al., Prognostic factors for lymphedema after primary treatment of breast carcinoma. Cancer, 2001. 92(7): p. 1783-7
Designed for Lymphoedema
-
The L‑Dex score, only available from ImpediMed, is designed to detect small lymphoedema-related fluid changes in the limbs.
-
L‑Dex compares the fluid in a limb at-risk for lymphoedema to a healthy limb in order to help detect lymphedema.
-
L‑Dex is FDA-cleared for: unilateral lymphoedema and bilateral lymphoedema, arms and legs, and women and men.
Demonstrated Outcomes
-
81% lower incidence of chronic cancer-related lymphoedema with BIS L‑Dex monitoring and intervention than with circumference monitoring in a meta-analysis of 67,000 patients
-
Statistically lower rates of chronic lymphoedema in high-risk patients and short-term and long-term follow-up
-
Consistent reduction in lymphoedema progression, study after study
SOZO Digital Health Platform
SOZO®
SOZO, the world’s most advanced, non-invasive BIS device, incorporates L-Dex technology to aid in the assessment of secondary lymphoedema and delivers a precise snapshot of fluid status and tissue composition in less than 30 seconds.
